Grafted Sertoli Cells Exert Immunomodulatory Non-Immunosuppressive Effects in Preclinical Models of Infection and Cancer
Cells · 2024
DOI: 10.3390/cells13060544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Sara Chiappalupi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy. Hauptthemen laut MEDLINE: Sertoli Cells, Carcinoma, Lewis Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Duchenne Parent Project, European Union's Horizon 2020, Italian Association for Cancer Research.
Abstract (Originalsprache)
The Sertoli cells (SeCs) of the seminiferous tubules secrete a multitude of immunoregulatory and trophic factors to provide immune protection and assist in the orderly development of germ cells. Grafts of naked or encapsulated SeCs have been proved to represent an interesting therapeutic option in a plethora of experimental models of diseases. However, whether SeCs have immunosuppressive or immunomodulatory effects, which is imperative for their clinical translatability, has not been demonstrated. We directly assessed the immunopotential of intraperitoneally grafted microencapsulated porcine SeCs (MC-SeCs) in murine models of fungal infection (Aspergillus fumigatus or Candida albicans) or cancer (Lewis lung carcinoma/LLC or B16 melanoma cells). We found that MC-SeCs (i) provide antifungal resistance with minimum inflammatory pathology through the activation of the tolerogenic aryl hydrocarbon receptor/indoleamine 2,3-dioxygenase pathway; (ii) do not affect tumor growth in vivo; and (iii) reduce the LLC cell metastatic cancer spread associated with restricted Vegfr2 expression in primary tumors. Our results point to the fine immunoregulation of SeCs in the relative absence of overt immunosuppression in both infection and cancer conditions, providing additional support for the potential therapeutic use of SeC grafts in human patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.
- Interuniversity Institute of Myology (IIM), 06132 Perugia, Italy.
- Consorzio Interuniversitario Biotecnologie (CIB), 34127 Trieste, Italy.
- Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.
- Centro Biotecnologico Internazionale di Ricerca Traslazionale ad indirizzo Endocrino, Metabolico ed Embrio-Riproduttivo (CIRTEMER), 06132 Perugia, Italy.
- Centro Universitario di Ricerca sulla Genomica Funzionale (CURGeF), 06132 Perugia, Italy.
ORCID-Profile: Monica Borghi, Francesca Riuzzi, Guglielmo Sorci
Förderung
- Duchenne Parent Project
- European Union's Horizon 2020
- Italian Association for Cancer Research
- Fondazione Umberto Veronesi
- European Union’s Horizon 2020 research and innovation program funding
- Fondazione Veronesi fellowship
- AIRC
Zitieren
APA
Chiappalupi, S., Salvadori, L., Borghi, M., Mancuso, F., Pariano, M., Riuzzi, F., Luca, G., Romani, L., Arato, I., & Sorci, G. (2024). Grafted Sertoli Cells Exert Immunomodulatory Non-Immunosuppressive Effects in Preclinical Models of Infection and Cancer. Cells. https://doi.org/10.3390/cells13060544
Vancouver
Chiappalupi S, Salvadori L, Borghi M, Mancuso F, Pariano M, Riuzzi F, et al. Grafted Sertoli Cells Exert Immunomodulatory Non-Immunosuppressive Effects in Preclinical Models of Infection and Cancer. Cells. 2024. doi:10.3390/cells13060544
BibTeX
@article{Chiappalupi2024,
author = {Chiappalupi, Sara and Salvadori, Laura and Borghi, Monica and Mancuso, Francesca and Pariano, Marilena and Riuzzi, Francesca and Luca, Giovanni and Romani, Luigina and Arato, Iva and Sorci, Guglielmo},
title = {Grafted Sertoli Cells Exert Immunomodulatory Non-Immunosuppressive Effects in Preclinical Models of Infection and Cancer},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13060544}
}
EUVIMED